Erythropoietin for newborn brain injury in low-resource settings
Treatments studied
Part of Brain & nervous system, Genetic & congenital clinical trials.
This Phase 3 trial studies whether erythropoietin (a medicine related to red-blood-cell growth) can improve outcomes for newborns with moderate to severe brain injury after birth. The study focuses on babies born in low- and middle-income countries and aims to reduce harm from this early brain condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Baby was born at 36 weeks or later, and weighed at least 1.8 kg at birth
- Baby shows signs of needing extra help right after birth or has abnormal blood tests early on (within the first hour)
- Baby is diagnosed with moderate or severe neonatal encephalopathy within 1 to 6 hours after birth
- Baby is not in immediate danger of dying at the time the study would start
- Baby can be brought back for follow-up at about 18 months (or families are likely to return)
- Baby was not given whole-body cooling (induced hypothermia) for treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether cooling a newborn’s body can help babies with mild brain injury after a difficult birth. It aims to see if cooling improves brain-related outcomes compared with standard care.
This study tests whether giving a medicine called erythropoietin to newborns who had a brain injury due to lack of oxygen can help them recover. It is for babies less than one month old who have this specific condition.
This early-phase study tests whether using a baby’s own cord blood stem cells is safe and feasible for newborns with brain injury from lack of oxygen around birth. It may help researchers find new ways to treat hypoxic-ischemic encephalopathy (brain injury due to oxygen deprivation) in addition to standard care like cooling.
This trial is for newborn babies who had an oxygen shortage around birth and now have severe brain injury. It aims to test approaches that may help improve outcomes after this kind of early-life brain damage.
This study looks at a blood test that might help check brain injury in newborns who had a lack of oxygen at birth. The test could give doctors more information to help care for your baby.
This Phase 1 trial studies whether giving erythropoietin (EPO) and melatonin is safe in very preterm infants who have bleeding in the brain (intraventricular hemorrhage) or significant nearby brain injury. It aims to see if these medicines can be given safely during the early days after birth.
Hear when a new Encephalopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.